Cipla, Hetero roll out Aranesp biosim; Judge backs Novartis' Exelon patents;

@FiercePharma: Now out: This week's issue of FierceVaccines. Weekly report | Follow @FiercePharma

@TracyStaton: Trending now at FiercePharma: Novo Nordisk lays out plans to recruit 6,000 workers in R&D, production. Story | Follow @TracyStaton

@EricPFierce: How much are the big dogs of Big Pharma paid? A lot. See the top 15 highest paid CEOs here. | Follow @EricPFierce

@CarlyHFierce: Czech scientists have a Lyme disease vaccine ready for animal use. A few of my favorite things in here, and Lyme disease isn't one of them. Story | Follow @CarlyHFierce

> India's Cipla teamed up with Hetero to launch a biosimilar version of Amgen's ($AMGN) anemia treatment Aranesp in its home country. Release | Report

> A Delaware judge found that generics maker Watson Laboratories, now owned by Actavis ($ACT), stepped on Novartis' ($NVS) patents for the Alzheimer's treatment patch Exelon. Release | Report

> U.S.-based Mylan ($MYL) pulled batches of an injectable antibiotic, made in Poland for sale under the Agila brand, because of possible impurities. Report

> The U.K.'s cost-effectiveness agency will hold an oral appeal hearing for the prostate cancer treatment Firmagon, which was approved in April, but for a limited patient group. Release

> The Indian generics maker Dr. Reddy's pulled more than 13,000 bottles of its copy of AstraZeneca's ($AZN) blood pressure treatment Toprol XL. Report

Medical Device News

@FierceMedDev: EnteroMedics up in early trading after mixed FDA panel vote. More | Follow @FierceMedDev

@StacyALawrence: Medtronic merger could give Covidien execs an $80M payout. Story | Follow @StacyALawrence

@MichaelGFierce: UPenn team combats Parkinson's with immunotherapy that targets neuron killers. Story from FierceBiotechResearch | Follow @MichaelGFierce

@EmilyWFierce: Single gene mutations that lower triglyceride levels could spur the development of a new class of heart disease drugs. Article | Follow @EmilyWFierce

> Data: Medtronic personalized defibrillator safer, cheaper. More

> Covidien endovascular unit could be target for cuts after Medtronic merger. Story

> Covidien recalls potentially faulty Hydrofinity guidewire. Article

Biotech News

@FierceBiotech: Navitor grabs a $23.5M A round to tackle a key crossroad for disease. More | Follow @FierceBiotech

@JohnCFierce: Man, that Burrill lawsuit makes for interesting reading. Story | Follow @JohnCFierce

@DamianFierce: J&J Innovation's summer class of biotechs targets obesity, insomnia, heart failure, cancer and more. News | Follow @DamianFierce

> Zafgen, Ardelyx bank $156M in IPOs, recalling biotech's winter boom. More

> J&J pays $30M to grab rights to Vertex program. Item

> Takeda dumps its top cancer contender after a late-stage struggle. Story

Vaccines News

> Merck, Sanofi JV wins anal cancer indication for Gardasil in EU. Story

> Themis Chikungunya prophylactic hits Phase I goal. More

> Pfizer puts the heat on Novartis with FDA MenB filing. Article

> Novartis submits Bexsero to FDA in race for MenB market. News

> MenB survivors call for Bexsero coverage in Australia. Item

> Novartis facility grabs FDA license to produce cell-culture vaccines. Report

Pharma Manufacturing News

> EMA GMP inspectors working group making updates for this year. Item

> Ranbaxy's FDA problems stymie launch of generic Nexium and the relief it would bring to consumers. More

> Dr. Reddy's initiates 2 recalls even as it invests to remove human error. Story

> Grifols doubles capacity with new U.S. plasma fractionation plant. Article

> Counterfeit antibiotics feed drug resistance, superbugs. News

> FDA finds fault with Chinese API maker. Report

And Finally... Americans slept more last year, but worked less, thanks to a groggy economy. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.